SCHEMBL840526

SCHEMBL840526

Cc1ccc(NC(=O)[C@@H](O)CO[C@H](C)CO[Si](C(C)C)(C(C)C)C(C)C)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.45
MAPT P10636 1/20 0.45
NPC1 O15118 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
ATM Q13315 1/20 0.38
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GCK P35557 2/20 0.37
ADRA2A P08913 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
TP53 P04637 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840527 1.00 RAB9A (0.45) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL850246 0.88 L3MBTL1 (0.51) RAB9ANPC1KMT2AALDH1A1HPGD
SCHEMBL839642 0.88 L3MBTL1 (0.51) RAB9ANPC1KMT2AALDH1A1HPGD
SCHEMBL839791 0.88 FFAR2 (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL839643 0.88 L3MBTL1 (0.51) RAB9ANPC1KMT2AALDH1A1HPGD
SCHEMBL839792 0.88 FFAR2 (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL839930 0.87 RAB9A (0.48) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL839929 0.87 RAB9A (0.48) RAB9AMAPTNPC1SMN1; SMN2MEN1
SCHEMBL839005 0.85 NOTUM (0.38) GCKKCNH2
SCHEMBL839004 0.85 NOTUM (0.38) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 RAB9A 3239/4885MAPT 3944/4885NPC1 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.